How The LifeMD (LFMD) Story Is Shifting Around GLP-1 Growth Plans And 2026 Expectations [Yahoo! Finance]
LifeMD, Inc. (LFMD)
Company Research
Source: Yahoo! Finance
LifeMD's fair value target currently sits at US$9.88, with the latest update keeping that figure unchanged from the prior US$9.88 estimate. Analysts link this steady target to a balance between stronger views around the GLP-1 focused growth plans, user retention and the 2026 outlook, as well as ongoing questions about how concentrated the story is in the weight loss management program. As you read on, you will see how these moving pieces shape the evolving LifeMD narrative and what it could mean for your own due diligence. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value LifeMD. What Wall Street Has Been Saying ?? Bullish Takeaways Mizuho upgraded LifeMD to Outperform from Neutral with a higher price target of US$8, citing what it views as a better than expected 2026 outlook and the role of oral GLP-1 drugs as an anchor for patient growth. Freedom Capital raised its price target to US$10 from US$8 after Q4
Show less
Read more
Impact Snapshot
Event Time:
LFMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LFMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LFMD alerts
High impacting LifeMD, Inc. news events
Weekly update
A roundup of the hottest topics
LFMD
News
- LifeMD to Report First Quarter 2026 Financial Results on May 6GlobeNewswire
- LifeMD® Now Offering Eli Lilly and Company’s Foundayo™ (orforglipron), a New GLP-1 Pill for Weight ManagementGlobeNewswire
- LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription ProgramGlobeNewswire
- Novo to sell Wegovy subscriptions on Hims, LifeMD, and others [Seeking Alpha]Seeking Alpha
- LifeMD: Comparing The High Yield Preferred Stock To An Options Income Strategy [Seeking Alpha]Seeking Alpha
LFMD
Earnings
- 3/9/26 - Beat
LFMD
Sec Filings
- 4/1/26 - Form 4
- 4/1/26 - Form 3
- 4/1/26 - Form 3
- LFMD's page on the SEC website